← Back to Search

Antifibrinolytic Agent

Active Comparator for Bleeding

Phase 2

Waitlist Available

Led By Marit Pearlman Shapiro

Research Sponsored by University of Hawaii

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Timeline

Screening 3 weeks

Treatment Varies

Follow Up at time of procedure

Awards & highlights

Study Summary

This trial will test whether using tranexamic acid can reduce bleeding during dilation and evacuation procedures for pregnant women.

Eligible Conditions

Blood Loss
Bleeding
Abortion
Dilation and Evacuation

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ at time of procedure

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~at time of procedure

This trial's timeline: 3 weeks for screening, Varies for treatment, and at time of procedure for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Intervention to control blood loss

Trial Design

2Treatment groups

Active Control

Placebo Group

Group I: Active ComparatorActive Control1 Intervention

1g tranexamic acid mixed in 100mL saline or lactated ringer given intravenously over 10 minutes at start of procedure

Group II: PlaceboPlacebo Group1 Intervention

100mL saline or lactated ringer without tranexamic acid added given intravenously over 10 minutes at start of procedure

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

University of HawaiiLead Sponsor

115 Previous Clinical Trials

54,641 Total Patients Enrolled

Society of Family PlanningOTHER

98 Previous Clinical Trials

17,086 Total Patients Enrolled

1 Trials studying Bleeding

230 Patients Enrolled for Bleeding

Marit Pearlman ShapiroPrincipal InvestigatorUniversity of Hawaii

Media Library

Tranexamic acid (Antifibrinolytic Agent) Clinical Trial Eligibility Overview. Trial Name: NCT04651166 — Phase 2

Bleeding Research Study Groups: Placebo, Active Comparator

Bleeding Clinical Trial 2023: Tranexamic acid Highlights & Side Effects. Trial Name: NCT04651166 — Phase 2

Tranexamic acid (Antifibrinolytic Agent) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04651166 — Phase 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What are the traditional indications for Active Comparator?

"Active Comparator can be prescribed in order to combat hyperfibrinolysis, hemophilia, or any intracranial bleeding."

Answered by AI

Are there still openings for volunteers to participate in this study?

"Affirmative. According to information made available on clinicaltrials.gov, this research initiative is actively recruiting volunteers; it was originally uploaded on February 15th 2022 and most recently modified on May 20th 2022. The current study requires 50 participants from a single medical centre."

Answered by AI

What prior investigations have utilized Active Comparator to assess outcomes?

"Currently, the medication Active Comparator is being trialled in 61 studies with 26 of those clinical trials reaching Phase 3. While a majority are situated in Kaohsiung City, Yanchao District, there are 185 different sites running tests for this drug."

Answered by AI

How many research participants are taking part in this clinical investigation?

"Affirmative. According to the data hosted on clinicaltrials.gov, this study, which was first advertised on February 15th 2022, is actively searching for enrollees. The trial needs 50 patients from 1 medical facility."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Effect of Prophylactic Tranexamic Acid on Bleeding Outcomes for Dilation and Evacuation

Marit Pearlman Shapiro 2022. "Effect of Prophylactic Tranexamic Acid on Bleeding Outcomes for Dilation and Evacuation". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04651166.